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Summary: 
 
This retrospective mirror-image observational study aimed to establish the effects of the long-
acting antipsychotic injection Paliperidone Palmitate (PP) on acute inpatient hospitalization 
rates. We utilized routinely collected clinical data to compare the number and length of acute 
patient admissions one year pre and post initiation of PP. A single cohort of 66 patients with a 
diagnosis of schizophrenia and who had received monthly injections of PP for at least one year 
were included in the analysis. The mean number of acute inpatient admissions fell from 0.86 in 
the year before PP initiation to 0.23 in the following year (p=0.001), and there was a numerical 
but non-significant decrease in the number of bed days from 32.48 to 31.22 over the study 
duration.  The median number of bed days in the year before PP initiation was 20, and in the 
year after initiation it was 0.  The median number of admissions also fell from 1 to 0 during the 
same period. The results of the study should be treated cautiously but suggest that patients 
with a diagnosis of schizophrenia who continue treatment with PP over 12 months experience a 
significant reduction in numbers of hospital admissions compared to the previous year. 
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A retrospective observational study of the effectiveness of Paliperidone Palmitate on acute 
inpatient hospitalization rates 
 
Introduction 
 
Schizophrenia is a severe mental illness that often requires treatment with antipsychotic 
medication for long periods in order to minimize the distress associated with symptoms and 
reduce the likelihood of relapse (Jablensky et al., 1992; Ascher-Svanum et al., 2006). Increases 
in the number of relapses and subsequent hospitalizations are closely associated with worse 
long-term patient outcomes (Falkai et al., 2006) and increased health care costs (Polsky et al., 
2006).  Due to these negative outcomes relapse prevention is a key therapeutic aim in the 
treatment of schizophrenia and antipsychotic medication plays a significant role (Olivares et al., 
2013). Although antipsychotic medications can improve symptoms, patient non-adherence with 
oral formulations of antipsychotics is very common and this is associated with a much higher 
chance of relapse (Byerly et al., 2007).  Some studies have shown that compared to oral 
medication the use of long-acting typical and atypical antipsychotic injections can improve 
treatment adherence and potentially reduce readmission rates over the longer term (Edwards 
et al., 2005; Haddad et al., 2009).  
 
Numerous long-acting atypical antipsychotic injections are now available for use, but the 
evidence about their effectiveness in terms of reducing numbers and lengths of hospitalizations 
is somewhat mixed. Within some prospective observational studies atypical long acting 
injections have been shown to reduce relapse rates and readmissions to hospital when 
compared to oral antipsychotics (Olivares et al., 2009; Chue et al., 2005), whilst some longer-
term controlled studies show no benefit of long-acting atypical injections over oral medications 
(Macfadden et al., 2010; Rosenheck et al., 2011).   
 
Different observational studies exploring the effectiveness of the same atypical antipsychotic 
drug have also produced some equivocal findings. For example, a number of studies have 
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measured the impact of long-acting risperidone injections on patient hospitalization rates; 
some of these studies have shown that it is effective in reducing inpatient stays (Taylor et al., 
2008), whilst others show an increase of admission days post initiation (Young and Taylor, 2006; 
Taylor and Cornelius, 2010).    
 
Long-acting Paliperidone Palmitate (PP) injection is an atypical antipsychotic licensed for the 
treatment of schizophrenia and as it has been only relatively recently available there are few 
studies that explore its effectiveness. PP has been licensed for use in the UK since early 2011 
and has been used our clinical setting since June 2011. Clinical trials have demonstrated the 
efficacy of PP in controlled research studies (Bishara, 2010), and a naturalistic observational 
cohort study suggests that PP was relatively well tolerated by patients, with 65% of 200 
patients still receiving the drug after one year  (Attard et al., 2013).  Only limited information is 
published about PP’s effectiveness in reducing the length and number of hospital admissions in 
real-life clinical practice. One such study conducted by Taylor and Olofinjana (2014) recently 
demonstrated through a 12 month prospective, non-interventional, observational study that 
the use of PP resulted in significant reductions in the number and length of hospital admissions 
per patient per year.   
 
Taylor and Olofinjana’ s 2014 study was conducted within a NHS Trust which provides mental 
health (MH)  services to patients with a different ethnic demographic profile (compared to our 
patient population) and who were primarily residing in an inner city area; due to this the results 
are not directly generalisable to our more rural/suburban clinical setting. Therefore, the current 
study aims to establish the potential effects of PP treatment in terms of effects on acute 
inpatient hospitalization rates in our MH trust. 
 
Methods 
 
The study was carried out in one NHS MH trust located in southern England and was approved 
by the Trusts’ clinical audit and effectiveness office as a service evaluation on the 9
th
 September 
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2014.  All data were anonymised and held securely in line with the Trust’s data protection 
policies.    
 
Key Inclusion Criteria 
 
We screened the electronic record data of male and female patients with a diagnosis of 
schizophrenia, aged 18-65 and who had been treated with PP in both acute inpatient and out-
patient settings.  Patients with a minimum of one year’s clinical data pre-initiation of PP 
recorded on the electronic patients record system and a minimum of one year’s clinical data 
recorded post-initiation of PP  were included in the analysis. Patients were only included if they 
had completed at least 12 months treatment with PP. Patients’ data also excluded if PP was 
being used out-of-license or if patients were switched from Clozapine to PP (as PP is not 
indicated for patients who are treatment resistant). 
 
Data Collection 
 
The number of acute inpatient admissions and number of associated bed days in the one year 
before and one year after PP initiation were obtained from patients’ records. We also gathered 
a range of other clinical and demographic data that were recorded in the patients’ electronic 
notes, including: gender, ethnicity, age at initiation of PP, employment status, marriage status, 
treatment setting, duration of contact with mental health services and responsiveness to PP 
treatment (as defined by HoNOS scores; Wing et al., 1998).   We wanted to focus on the use of 
acute inpatient services so we excluded all hospital admissions and related bed days that 
related to either forensic or specialist rehabilitation settings both pre and post PP initiation. Our 
clinical rationale for excluding these admissions was that the lengths of hospitalization and 
criteria for patient discharge were more likely to be related to court restrictions and the need 
for ongoing rehabilitation than the effects of antipsychotic treatment.   
 
Primary (a-priori) analysis approach 
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 The primary endpoint for this study was the mean number of hospital admissions and number 
of bed days 1 year preceding initiation of PP and mean number of hospital admissions and 
number of bed days in the one year following initiation of PP. Whether the patient was initiated 
in the community or in the hospital setting, the mirror date was set at 2 weeks after PP 
initiation (see figure 1). We chose 14 days as our mirror point in an attempt to account for the 
bed days that may be associated with efficacy failure of the previous drug. This is an important 
consideration because it is estimated that 58% percent of costs incurred during the first week 
on a new antipsychotic are most likely due to treatment ineffectiveness of the previous 
antipsychotic rather than the failure of the newly introduced medication (Faries et al., 2009). 
Our strategy was based on reports that generally a satisfactory therapeutic response to 
antipsychotics is usually seen within two weeks after initiation (Glick et al., 2009; Leucht et al., 
2005) and that on average PP reaches peak plasma concentration around 13 days after the first 
injection into the deltoid muscle (Sheehan et al, 2012). 
 
Post-hoc sensitivity analyses: 
 
For reasons of transparency and comparability with previously published similar studies we also 
adopted an additional post-hoc sensitivity analyses strategy which is the same as that described 
by Taylor and Olofinjana (2014).  In this secondary analysis we used the date of PP initiation as 
the mirror point for all outpatients, but for patients who started on PP as an inpatient we 
compared the mean hospitalizations rates pre PP with the mean number in the year following 
discharge from the index admission (effectively discounting bed days from the post PP 
calculation where they were part of the index admission– see figure 2).  
 
Data analysis strategy: 
 
Data were analysed using the IBM SPSS statistical package version 21 (IBM Corp, 2012). The 
distribution of numbers of admissions and bed days was non-normal as shown by the 
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histograms and Normal Q-Q plot. This was additionally confirmed by the skewness and kurtosis 
indexes of the variables as well as the corresponding Kolmogorov-Smirnov and Shapiro-Wilk 
tests of normality. We therefore used Wilcoxon signed rank tests and bootstrap paired sample 
t-tests to test the null hypothesis of no difference in number of admissions and bed-days pre 
and post PP-initiation. 
 
Results 
 
Data were initially retrieved from 148 patients.  After applying our inclusion criteria a final 
sample of 66 patients was retained. The main reasons for excluding cases related to not having 
a minimum of one year pre and sufficient post PP initiation data recorded or patients not 
having a diagnosis of schizophrenia. All PP discontinuers were excluded from the analysis in line 
with the study inclusion criteria.  We initially intended to explore responsiveness to PP 
treatment (as defined by routinely recorded HoNOS scores), but unfortunately due to 
sparseness of data and the irregularity in which scores were recorded we were left with only 9 
patients’ data that could be analyzed and we therefore had to abandon this approach due to 
the small sample size.    
 
Demographic and clinical characteristics 
 
Most patients included in this study were white, single males that were either unemployed or 
defined as being long-term sick.  The mean age of the participants was 40.86 and they had been 
in contact with MH services on average for almost 10 years. Demographic information about 
the sample is summarized in table 1.   
 
Number of Admissions and Bed days 
 
The average number of admissions in the year pre-PP initiation was 0.86, SD= 0.88, while the 
average number of admissions in the year post-PP initiation was 0.23, SD=0.55 and the median 
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number of admissions reduced from 1 to 0 over the study duration. The Wilcoxon test (<0.0001) 
and the Bootstrap paired sample t-test (0.64, 95% CI: 0.42, 0.85, p=0.001) showed a significant 
reduction in the number of admissions post PP initiation.  
 
There was a numerical decrease in mean number of bed days from one year before PP initiation 
32.48 (SD=44.76) to one year post-PP initiation 31.22 (SD=53.33). The median number of bed 
days decreased from 20 to 0. The Wilcoxon test (p=0.50) and the Bootstrap t-test (mean diff= 
1.26, 95% CI: 10.66, 13.95, p=0.84) showed a non-significant difference in bed days between 
pre and post initiation.  
 
The histograms (figure 3) illustrate that although many patients had a reduction in bed days, 
some patients with long admissions post PP initiation have skewed the mean. These 7 patients 
had long admissions for a number of reasons, including: disturbed behavior requiring intensive 
care, psychiatric co-morbidities, complex psychiatric needs and placement issues. The 
distribution of pre-post differences in number of admissions and bed days was not significantly 
different across both treatment settings and genders.  
 
Sensitivity analysis 
 
Please see table 2 for comparison of pre and post PP differences according to the two different 
approaches used to calculate before and after outcomes.  The post-hoc sensitivity analyses 
used the same analysis tests as our primary approach and results in significant improvements in 
average admissions from 0.86 to 0.23 and a reduction in annual bed days from 26.77 before PP, 
to 11.23 in the following year (Wilcoxon p=0.003; Bootstrap t-test= 15.55, CI: 3.66, 28.86; 
p=0.016).    
 
Discussion 
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Our primary endpoint analysis shows that the monthly administration of long-acting injectable 
PP in 66 patients with schizophrenia over one year was associated with a significant reduction 
in the mean number of acute inpatient admissions when compared to the previous year.  There 
was also a numerical (but non-significant) decrease in average number of bed days during the 
year following PP initiation.  The median number of admissions reduced from 1 to 0 in the year 
after starting PP and median amount of bed days decreased from 20 to 0 over the same period. 
The primary strategy that we used to calculate pre and post outcomes is less likely to favour the 
new drug than those studies which discount all index admission days from the post treatment 
group by inserting the mirror point at the point of discharge (i.e. Taylor and Olofijana, 2014), 
and therefore our results could arguably present a realistic, but more conservative picture.  
 
Due to a current lack of evidence from observational naturalistic studies of PP it is problematic 
to compare and contrast our results with previously published outcomes. Direct comparisons of 
our findings with those of Taylor and Olofijana (2014) are also complicated by the differing 
clinical contexts, their larger sample size, inclusion of non-continuers of PP and some of the 
demographic characteristics of participants. Despite the ethnicity and percentage of women 
patients being very different in our study compared to Taylor and Olofijana’s, there are some 
other demographics that are very comparable: 45% of participants in each study were initiated 
in outpatient settings, the mean duration of illness in both studies was around nine years and 
the average age was 41 in our study (vs. 43 years).  Their primary analysis method involved 
comparing the average yearly rates/lengths of hospitalization during the three years prior to PP 
initiation with the mean number of hospitalizations post PP, and for patients initiated as 
inpatients this was calculated from the year after the point of discharge from an index 
admission. This approach produced significant reductions in the mean number of bed days 
(38.78 to 23.09) and admissions (0.67 to 0.49) after starting PP. However, using a mirror point 
inserted at the time of initiation for all patents they found a significant reduction in admissions 
of 0.67 to 0.51 and an increase of bed days from 38.78 to 56.75; findings which are less 
favourable to the results from our primary endpoint analysis. Similarly to Taylor and Olofijana’s 
study the median number of admissions and bed days in our study was 0 in the year after PP 
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initiation (irrespective of which method was used to calculate this).  When we adopted the 
same method of analysis as Taylor and Olofijana’s study, our results show a similar reduction in 
bed days and a greater reduction in the number of admissions for patients continuing PP for at 
least a year following initiation.   
 
The findings resulting from our sensitivity analysis highlight how the varying mirror-points used 
to calculate before and after outcomes can have a large influence on results.  Our post-hoc 
analysis is certainly more likely to favour the new drug as it discounts all index admission bed 
days from the post PP calculations; as could be expected this shows large and significant 
reductions in hospitalizations in the year following PP. A number of other researchers (i.e. 
Taylor and Olofijana, 2014; Faries et al., 2009) have also demonstrated that the different 
strategies used in mirror-image studies to handle acute-service use occurring just after an 
antipsychotic medication change can have profound effects on study findings. Strategies that 
compare the bed days in the year pre-initiation with the bed days in the year after patients are 
discharged from the index admission tend to favour the new drug. Whilst approaches that 
attribute bed days from an index admission to post-treatment immediately following initiation 
are likely to underestimate positive effects of the new antipsychotic (Taylor and Olofijana, 2014; 
Faries et al., 2009). Therefore, using a mirror point of two weeks post initiation seemed an 
appropriate way for us to address these issues and minimize the risk of over or underestimating 
the effects of PP on hospitalizations.  
 
Given the relatively expensive cost of PP it is worth considering its potential cost-effectiveness 
in our study population. A widely used and broadly illustrative method to estimate cost 
effectiveness is to calculate savings made on reduced hospitalizations and offset these against 
the costs of medication (Bernardo, et al., 2006), but as our sensitivity analysis shows, in this 
study the results will vary based in the approach used to measure before and after effects.  
 
The average monthly maintenance dose of PP in this study is 102mg (excluding any additional 
amounts for the initial loading dose) and therefore the conservative annual purchase cost per 
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patient is around £3,769.  Given that the Trust’s average acute admission length is 31.4 days, 
and one acute bed day in our Trust is costed at £375, this equates to an average cost of £11,775 
per admission; as the bootstrap t-test results in our primary endpoint analysis show a 
significant reduction of 0.64 admissions per patient in the year following PP, this suggests an 
average saving of £7,536, which clearly outweighs the annual PP cost of £3,769.  Our sensitivity 
analysis (which is arguably more likely to favour PP) additionally demonstrates a significant 
reduction of 15.55 bed days post initiation and this equates to a potential acute hospitalization 
cost saving of £2,062 per patient initiated on PP (£5,831 - £3,769). These (albeit somewhat 
crude) calculations suggest that PP is largely cost-effective in our clinical setting. 
 
Due to the limitations of the retrospective observational study design and the relatively small 
sample size our results should be treated with caution, particularly as any changes in rates and 
lengths of admissions may be due to numerous possible extraneous influences. We cannot 
certainly establish that PP reduces the number of acute inpatient admissions or is more/less 
superior to other medications because this is an uncontrolled study without a comparison 
group. We did not include a control arm in our study and therefore changes in the bed days and 
admission rates observed may be a reflection of background variation irrespective of treatment. 
We were also not able to access information about which drugs patients were prescribed 
before initiation and therefore we are not able to identify any potential associations between 
these and differences in rates of hospitalization.    
 
All data originated from patients who were adherent with their prescribed PP treatment over at 
least a year, and as a result our findings will be more positive than those studies which include 
data from patients who have discontinued treatment.  Additionally, patients were not 
randomised to receive treatment and therefore decisions about which patients were selected 
by prescribers to start PP is likely to have been based on their perceived increased likelihood of 
who would respond to the drug. Similarly, local prescribing guidelines suggest that only patients 
who have had an adequate previous response to oral risperidone, which is almost identical to 
PP in its pharmacological properties (Spina and Cavallaro, 2008; Bishara and Taylor, 2008) can 
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be considered for PP; this may have resulted in patients who respond to, but are non-adherent 
with oral risperidone starting PP and therefore the patients included in this study are likely to 
represent the most responsive population.  
 
Despite these limitations, our findings are based on routinely collected clinical data in a real-
world setting. We have not excluded any patients with substance misuse or physical/mental 
health co-morbidities, there were no major changes in hospital admission policy or bed closures 
which are likely to have affected rates of hospitalization, and therefore the results may 
plausibly reflect the naturalistic outcomes of patients with schizophrenia who continue PP 
treatment within the MH trust studied.  Although our results are promising, in order to more 
certainly measure the effects of PP on the use of acute inpatient services future observational 
studies should consider using a prospective design with a comparison group.     
 
In conclusion, this observational study suggests that PP initiation in patients with a diagnosis of 
schizophrenia (and who continue with regular monthly injections over 12 months) is likely to be 
associated with a significant reduction in the number of hospital admissions when compared to 
the previous year.  
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 Table 1: Demographics of participants 
 
 
Parameter N= 66 
Age at initiation of PP:  
    Mean (SD),  
    Range  
 
40.86 (12.87) 
18-65 
Duration of contact with services at PP initiation (N=63) 
    Mean (SD), 
    Range 
 
9.70 (8.20) 
1-50 
Sex, n (%) 
    Male 
    Female 
 
47 (71) 
19 (29) 
Ethnicity, n (%) 
    Black 
    White 
    Other 
    Unknown 
 
3 (4.5) 
50 (76.7) 
10 (15.0) 
3 (4.5) 
Care setting at PP initiation, n (%)  
     Inpatient  
     Outpatient 
 
36 (54.5) 
30(45.5) 
Employment status, n (%) 
     Employed 
     Unemployed 
     Long-term sick 
     Other 
 
4 (6.1) 
21 (31.8) 
23 (34.8) 
18 (27.2) 
Marital status, n (%) 
     Married 
     Single 
    Divorced/Separated/Other 
 
5 (7.5) 
42 (63.6) 
19 (28.7) 
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Table 2: Differences between 1 year pre and post PP hospitalization rates 
 
 
 (i) Mirror point inserted at 14 days post PP initiation for all patients (see figure 1). 
(ii) Mirror point inserted at PP initiation for all patients and index admission bed days post PP  
disregarded for patients initiated whilst in hospital (see figure 2).   
* Significant at P<0.05 
PP, Paliperidone Palmitate 
  
Analysis 
strategy 
(n=66) 
Admissions in 
one year 
before PP 
 
Mean (SD) 
 
Median 
Admissions in 
one year after 
PP 
 
Mean (SD) 
 
Median 
Bootstrap t 
test :mean 
difference, 
(95%CI), p 
value  
Wilcoxon 
signed rank 
test (p)  
Bed days in one 
year before PP  
 
 
Mean (SD) 
 
Median 
Bed days in one 
year after PP 
 
 
Mean (SD) 
 
Median 
Bootstrap t 
test :mean 
difference, 
(95%CI), p 
value  
Wilcoxon 
signed rank 
test (p)  
(i) Primary 
end point 
analysis  
 
 
0.86 (0.88) 
 
 
 
(Median = 1) 
 
0.23 (0.55) 
 
 
 
(Median = 0) 
 
0.64  
(0.42, 0.85) 
P=0.001* 
 
p<0.0001* 
 
32.48  (44.76) 
 
 
 
(Median = 20) 
 
31.22 (53.33) 
 
 
 
(Median = 0) 
 
1.26  
(-10.66,13.95) 
p=0.84 
 
p=0.50 
(ii) Sensitivity   
analysis  
 
0.86 (0.88) 
 
 
 
(Median =1) 
 
0.23 (0.55) 
 
 
 
(Median =0) 
 
0.64  
(0.42, 0.85) 
P=0.001* 
 
 
p<0.0001* 
 
26.77 (43.17) 
 
 
 
(Median =12) 
 
11.23 (30.41) 
 
 
 
(Median =0) 
 
15.55  
(3.66, 28.86) 
p=0.016* 
 
p= 0.003* 
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Figure 1:  Schematic representation of primary end-point analysis (all patients) 
 
 
 
 
 
Mirror point  
 
 PP initiation  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
            14  
          Days           One year after PP  
One year before PP initiation 
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Figure 2:  Schematic representation of sensitivity analysis  
(Inpatient initiated patients) 
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Figure 3:  Histograms of bed day’s pre and post PP  
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